The marine-derived fungal metabolite, terrein, inhibits cell proliferation and induces cell cycle arrest in human ovarian cancer cells

Chen,Yi-Fei; Wang,Shu-Ying; Shen,Hong; Yao,Xiao-Fen; Zhang,Feng-Li; Lai,Dongmei

doi:10.3892/ijmm.2014.1964

The marine-derived fungal metabolite, terrein, inhibits cell proliferation and induces cell cycle arrest in human ovarian cancer cells

Authors:
- Yi-Fei Chen
- Shu-Ying Wang
- Hong Shen
- Xiao-Fen Yao
- Feng-Li Zhang
- Dongmei Lai
View Affiliations

Affiliations: The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200030, P.R. China, Marine Biotechnology Laboratory, State Key Laboratory of Microbial Metabolism and School of Life Sciences and Biotechnology, Shanghai Jiaotong University, Shanghai 200240, P.R. China
Published online on: October 13, 2014 https://doi.org/10.3892/ijmm.2014.1964
Pages: 1591-1598

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The difficulties faced in the effective treatment of ovarian cancer are multifactorial, but are mainly associated with relapse and drug resistance. Cancer stem-like cells have been reported to be an important contributor to these hindering factors. In this study, we aimed to investigate the anticancer activities of a bioactive fungal metabolite, namely terrein, against the human epithelial ovarian cancer cell line, SKOV3, primary human ovarian cancer cells and ovarian cancer stem-like cells. Terrein was separated and purified from the fermentation metabolites of the marine sponge-derived fungus, Aspergillus terreus strain PF26. Its anticancer activities against ovarian cancer cells were investigated by cell proliferation assay, cell migration assay, cell apoptosis and cell cycle assays. The ovarian cancer stem-like cells were enriched and cultured in a serum-free in vitro suspension system. Terrein inhibited the proliferation of the ovarian cancer cells by inducing G2/M phase cell cycle arrest. The underlying mechanisms involved the suppression of the expression of LIN28, an important marker gene of stemness in ovarian cancer stem cells. Of note, our study also demonstrated the ability of terrein to inhibit the proliferation of ovarian cancer stem-like cells, in which the expression of LIN28 was also downregulated. Our findings reveal that terrein (produced by fermention) may prove to be a promising drug candidate for the treatment of ovarian cancer by inhibiting the proliferation of cancer stem-like cells.

View Figures

View References

1	Schwartz PE: Current diagnosis and treatment modalities for ovarian cancer. Cancer Treat Res. 107:99–118. 2002.PubMed/NCBI
2	Cho KR and Shih IeM: Ovarian cancer. Annu Rev Pathol. 4:287–313. 2009. View Article : Google Scholar
3	Sudo T: Molecular-targeted therapies for ovarian cancer: prospects for the future. Int J Clin Oncol. 17:424–29. 2012. View Article : Google Scholar : PubMed/NCBI
4	Foster R, Buckanovich RJ and Rueda BR: Ovarian cancer stem cells: working towards the root of stemness. Cancer Lett. 338:147–157. 2013. View Article : Google Scholar : PubMed/NCBI
5	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
6	Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005. View Article : Google Scholar
7	Dalerba P, Cho RW and Clarke MF: Cancer stem cells: models and concepts. Annu Rev Med. 58:267–284. 2007. View Article : Google Scholar : PubMed/NCBI
8	Nguyen LV, Vanner R, Dirks P and Eaves CJ: Cancer stem cells: an evolving concept. Nat Rev Cancer. 12:133–143. 2012.PubMed/NCBI
9	Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG and Parada LF: A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 488:522–526. 2012. View Article : Google Scholar : PubMed/NCBI
10	Driessens G, Beck B, Caauwe A, Simons BD and Blanpain C: Defining the mode of tumour growth by clonal analysis. Nature. 488:527–530. 2012. View Article : Google Scholar : PubMed/NCBI
11	Bapat SA, Mali AM, Koppikar CB and Kurrey NK: Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 65:3025–3029. 2005.PubMed/NCBI
12	Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, et al: Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA. 103:11154–11159. 2006. View Article : Google Scholar : PubMed/NCBI
13	Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, et al: Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68:4311–4320. 2008. View Article : Google Scholar : PubMed/NCBI
14	Kondo T, Setoguchi T and Taga T: Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA. 101:781–786. 2004. View Article : Google Scholar : PubMed/NCBI
15	Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K and Tang DG: Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2⁺ and ABCG2⁻ cancer cells are similarly tumorigenic. Cancer Res. 65:6207–6219. 2005. View Article : Google Scholar : PubMed/NCBI
16	Calcagno AM, Fostel JM, To KK, Salcido CD, Martin SE, Chewning KJ, Wu CP, et al: Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. Br J Cancer. 98:1515–1524. 2008. View Article : Google Scholar : PubMed/NCBI
17	Schmandt RE, Broaddus R, Lu KH, Shvartsman H, Thornton A, Malpica A, Sun C, et al: Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-β in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer. 98:758–764. 2003.
18	Ma L, Lai D, Liu T, Cheng W and Guo L: Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3. Acta Biochim Biophys Sin. 42:593–602. 2010. View Article : Google Scholar : PubMed/NCBI
19	Lai D, Wang F, Chen Y, Wang C, Liu S, Lu B, Ge X, et al: Human ovarian cancer stem-like cells can be efficiently killed by γδ T lymphocytes. Cancer Immunol Immunother. 61:979–989. 2012.PubMed/NCBI
20	Liu T, Cheng W, Lai D, Huang Y and Guo L: Characterization of primary ovarian cancer cells in different culture systems. Oncol Rep. 23:1277–1284. 2010.PubMed/NCBI
21	Luo X, Dong Z, Chen Y, Yang L and Lai D: Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway. Cell Prolif. 46:436–446. 2013. View Article : Google Scholar : PubMed/NCBI
22	Raistrick H and Smith G: Studies in the biochemistry of micro- organisms: the metabolic products of Aspergillus terreus Thom. A new mould metabolic product-terrein. Biochem J. 29:606–611. 1935.PubMed/NCBI
23	Ghisalberti EL, Narbey MJ and Rowland CY: Metabolites of Aspergillus terreus antagonistic towards the take-all fungus. J Nat Prod. 53:520–522. 1990.
24	Arakawa M, Someno T, Kawada M and Ikeda D: A new terrein glucoside, a novel inhibitor of angiogenin secretion in tumor angiogenesis. J Antibiot (Tokyo). 61:442–448. 2008. View Article : Google Scholar : PubMed/NCBI
25	Park SH, Kim DS, Kim WG, Ryoo IJ, Lee DH, Huh CH, Youn SW, Yoo ID and Park KC: Terrein: a new melanogenesis inhibitor and its mechanism. Cell Mol Life Sci. 61:2878–2885. 2004. View Article : Google Scholar : PubMed/NCBI
26	Phattanawasin P, Pojchanakom K, Sotanaphun U, Piyapolrungroj N and Zungsontiporn S: Weed growth inhibitors from Aspergillus fischeri TISTR 3272. Nat Prod Res. 21:1286–1291. 2007.PubMed/NCBI
27	Kim DS, Cho HJ, Lee HK, Lee WH, Park ES, Youn SW and Park KC: Terrein, a fungal metabolite, inhibits the epidermal proliferation of skin equivalents. J Dermatol Sci. 46:65–68. 2007. View Article : Google Scholar : PubMed/NCBI
28	Lee JC, Yu MK, Lee R, Lee YH, Jeon JG, Lee MH, Jhee EC, Yoo ID and Yi HK: Terrein reduces pulpal inflammation in human dental pulp cells. J Endod. 34:433–437. 2008. View Article : Google Scholar : PubMed/NCBI
29	Lee YH, Lee NH, Bhattarai G, Oh YT, Yu MK, Yoo ID, Jhee EC and Yi HK: Enhancement of osteoblast biocompatibility on titanium surface with Terrein treatment. Cell Biochem Funct. 28:678–685. 2010. View Article : Google Scholar : PubMed/NCBI
30	Kim DS, Lee HK, Park SH, Lee S, Ryoo IJ, Kim WG, Yoo ID, et al: Terrein inhibits keratinocyte proliferation via ERK inactivation and G₂/M cell cycle arrest. Exp Dermatol. 17:312–317. 2008. View Article : Google Scholar : PubMed/NCBI
31	Xu B, Yin Y, Zhang F, Li Z and Wang L: Operating conditions optimization for (+)-terrein production in a stirred bioreactor by Aspergillus terreus strain PF-26 from marine sponge Phakellia fusca. Bioprocess Biosyst Eng. 35:1651–1655. 2012. View Article : Google Scholar : PubMed/NCBI
32	Yin Y, Gao Q, Zhang F and Li Z: Medium optimization for the high yield production of single (+)-terrein by Aspergillus terreus strain PF26 derived from marine sponge Phakellia fusca. Process Biochem. 47:887–891. 2012. View Article : Google Scholar
33	Chen YF, Dong Z, Xia Y, Tang J, Peng L, Wang S and Lai D: Nucleoside analog inhibits microRNA-214 through targeting heat-shock factor 1 in human epithelial ovarian cancer. Cancer Sci. 104:1683–1689. 2013. View Article : Google Scholar : PubMed/NCBI
34	Cicenas J and Valius M: The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol. 137:1409–1418. 2011. View Article : Google Scholar : PubMed/NCBI
35	Collins I and Garrett MD: Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol. 5:366–373. 2005. View Article : Google Scholar : PubMed/NCBI
36	Hafner M, Max KE, Bandaru P, Morozov P, Gerstberger S, Brown M, Molina H and Tuschl T: Identification of mRNAs bound and regulated by human LIN28 proteins and molecular requirements for RNA recognition. RNA. 19:613–626. 2013. View Article : Google Scholar : PubMed/NCBI
37	Li N, Zhong X, Lin X, Guo J, Zou L, Tanyi JL, Shao Z, et al: Lin-28 homologue A (LIN28A) promotes cell cycle progression via regulation of cyclin-dependent kinase 2 (CDK2), cyclin D1 (CCND1), and cell division cycle 25 homolog A (CDC25A) expression in cancer. J Biol Chem. 287:17386–17397. 2012. View Article : Google Scholar : PubMed/NCBI
38	Moss EG, Lee RC and Ambros V: The cold shock domain protein LIN-28 controls developmental timing in C. elegans and is regulated by the lin-4 RNA. Cell. 88:637–646. 1997. View Article : Google Scholar : PubMed/NCBI
39	Shyh-Chang N and Daley GQ: Lin28: primal regulator of growth and metabolism in stem cells. Cell Stem Cell. 12:395–406. 2013. View Article : Google Scholar : PubMed/NCBI
40	Xu B, Zhang K and Huang Y: Lin28 modulates cell growth and associates with a subset of cell cycle regulator mRNAs in mouse embryonic stem cells. RNA. 15:357–361. 2009. View Article : Google Scholar : PubMed/NCBI
41	Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, O’Sullivan M, et al: Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 41:843–848. 2009. View Article : Google Scholar : PubMed/NCBI
42	Lu L, Katsaros D, Shaverdashvili K, Qian B, Wu Y, de la Longrais IA, Preti M, et al: Pluripotent factor lin-28 and its homologue lin-28b in epithelial ovarian cancer and their associations with disease outcomes and expression of let-7a and IGF-II. Eur J Cancer. 45:2212–2218. 2009. View Article : Google Scholar : PubMed/NCBI
43	Peng S, Maihle NJ and Huang Y: Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. Oncogene. 29:2153–2159. 2010. View Article : Google Scholar : PubMed/NCBI
44	Yang X, Lin X, Zhong X, Kaur S, Li N, Liang S, Lassus H, et al: Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer Res. 70:9463–9472. 2010. View Article : Google Scholar : PubMed/NCBI
45	Ma W, Ma J, Xu J, Qiao C, Branscum A, Cardenas A, Baron AT, et al: Lin28 regulates BMP4 and functions with Oct4 to affect ovarian tumor microenvironment. Cell Cycle. 12:88–97. 2013. View Article : Google Scholar : PubMed/NCBI
46	Sanchez-Garcia I, Vicente-Duenas C and Cobaleda C: The theoretical basis of cancer-stem-cell-based therapeutics of cancer: can it be put into practice? Bioessays. 29:1269–1280. 2007. View Article : Google Scholar : PubMed/NCBI